Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

F. Anthony Greco, Philip Bonomi, Jeffrey Crawford, Karen Kelly, Yun Oh, Wendy Halpern, Larry Lo, Gilles Gallant, Jerry Klein

Research output: Contribution to journalArticlepeer-review

151 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences